What's new? Log in Free sign up

Imunon (IMNN) News and press releases

Company Profile

News

From Benzinga Pro

IMUNON Announces Abstract Accepted For Presentation At The American Association for Cancer Research Annual Meeting On Tuesday, April 18, 2023

Biotech, News, FDA, Events, General

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company's DNA-based immunotherapy has been accepted for presentation at the

12 Health Care Stocks Moving In Thursday's After-Market Session

IMUNON CEO Issues Letter To Shareholders; Reviews 2022 Accomplishments; Sets Forth 2023 Milestones And Long-Term Vision

News, Guidance, Management

IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company, today announced that Dr. Corinne Le Goff, the company's president and chief executive officer, has issued the following letter to

IMUNON And Break Through Cancer Commence Enrollment In A Phase 1/2 Clinical Study Of IMNN-001 In Combination With Avastin In Advanced Ovarian Cancer

Biotech, News, FDA, General

The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ and CAMBRIDGE, MA, Feb. 27, 2023 (GLOBE NEWSWIRE)

12 Health Care Stocks Moving In Tuesday's After-Market Session

IMUNON Receives $1.6M From Sale Of Its New Jersey Net Operating Losses

News, Contracts, Asset Sales

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025 The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ, Jan. 12,

IMUNON Enters into Collaborative Research Agreement With The Wistar Institute's Vaccine & Immunotherapy Center To Research IMUNON's PLACCINE Vaccine Platform

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research located in the heart of University City, Philadelphia, through its Vaccine &

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 258 companies hit new 52-week lows.

Press releases

From Benzinga Pro

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ:IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company's DNA-based immunotherapy has been

IMUNON CEO Issues Letter to Shareholders

Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage biotechnology company, today

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ, Jan. 12, 2023

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform

LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.